Research map: HER2 ‐targeting zongertinib shows early activity in untreated advanced HER2 ‐mutant NSCLC

Back to the article

Papers in this map

  1. First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer · John Victor Heymach · 2026 · 14 citations · Cited by this paper
  2. New data inform decision‐making for breast cancer surgeries · 2026 · Related
  3. DELII: Ultralow‐dose nivolumab extended overall survival after prior systemic therapy · 2026 · Related
  4. Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B‐cell lymphoma, including the post‐CAR T‐cell therapy setting: A meta‐analysis · 2026 · Related
  5. Most older patients with advanced cancer prioritize QOL over extending survival · 2026 · Related
  6. Demographic, birth, parental characteristics, and the risk of early‐onset colorectal cancer: A population‐based nested case‐control study in California · 2026 · Related
  7. Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions · 2026 · Related
  8. First‐line CDK4/6 inhibitors fail to improve overall survival in advanced breast cancer · 2026 · Related
  9. EXPRESSION OF CONCERN: Prolyl Hydroxylase‐2 (PHD2) Exerts Tumor‐Suppressive Activity in Pancreatic Cancer† · 2026 · Related
  10. Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma · 2026 · Related
  11. Sexual health behaviors and contraceptive practices among Canadian childhood, adolescent, and young adult cancer survivors and controls · 2026 · Related

Source: OpenAlex (CC0)